Works by Pant, Shubham

Results: 74
    1
    2

    A phase I/II trial of avelumab combinations with ivuxolimab, utomilumab, and radiation therapy in patients with advanced gastrointestinal malignancies.

    Published in:
    Oncologist, 2025, v. 30, n. 3, p. 1, doi. 10.1093/oncolo/oyaf032
    By:
    • Ahmed, Jibran;
    • Knisely, Anne;
    • Torrado, Carlos;
    • Stephen, Bettzy;
    • Yang, Yali;
    • Song, Juhee;
    • Alshawa, Anas;
    • Zarifa, Abdulrazzak;
    • Jhingran, Anuja;
    • Koay, Eugene J;
    • Morris, Van Karlyle;
    • Javle, Milind;
    • Wolff, Robert A;
    • Meric-Bernstam, Funda;
    • Pant, Shubham;
    • Rodon, Jordi;
    • Naing, Aung
    Publication type:
    Article
    3

    Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma.

    Published in:
    Oncologist, 2025, v. 30, n. 1, p. 1, doi. 10.1093/oncolo/oyae182
    By:
    • Yousef, Mahmoud;
    • Hurd, Mark W;
    • Yousef, Abdelrahman;
    • Ludmir, Ethan B;
    • Pillai, Ashwathy B;
    • Peterson, Jennifer;
    • Koay, Eugene J;
    • Albarouki, Sali;
    • Tzeng, Ching-Wei;
    • Snyder, Rebecca;
    • Katz, Matthew H G;
    • Wang, Huamin;
    • Overman, Michael J;
    • Maitra, Anirban;
    • Pant, Shubham;
    • Smaglo, Brandon G;
    • Wolff, Robert A;
    • Yao, James;
    • Shen, John P;
    • Zhao, Dan
    Publication type:
    Article
    4

    Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers.

    Published in:
    Oncologist, 2024, v. 29, n. 6, p. 493, doi. 10.1093/oncolo/oyae011
    By:
    • Ngoi, Natalie Y L;
    • Tang, Tin-Yun;
    • Gaspar, Catia F;
    • Pavlick, Dean C;
    • Buchold, Gregory M;
    • Scholefield, Emma L;
    • Parimi, Vamsi;
    • Huang, Richard S P;
    • Janovitz, Tyler;
    • Danziger, Natalie;
    • Levy, Mia A;
    • Pant, Shubham;
    • Armas, Anaemy Danner De;
    • Kumpula, David;
    • Ross, Jeffrey S;
    • Javle, Milind;
    • Ahnert, Jordi Rodon
    Publication type:
    Article
    5
    6
    7

    Pancreas Cancer‐Associated Pain Management.

    Published in:
    Oncologist, 2021, v. 26, n. 6, p. e971, doi. 10.1002/onco.13796
    By:
    • Coveler, Andrew L.;
    • Mizrahi, Jonathan;
    • Eastman, Bory;
    • Apisarnthanarax, Smith "Jim";
    • Dalal, Shalini;
    • McNearney, Terry;
    • Pant, Shubham
    Publication type:
    Article
    8
    9

    Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study.

    Published in:
    2019
    By:
    • George, Goldy C;
    • Iwuanyanwu, Eucharia C;
    • Buford, Adrianna S;
    • Piha-Paul, Sarina A;
    • Subbiah, Vivek;
    • Fu, Siqing;
    • Karp, Daniel D;
    • Pant, Shubham;
    • Hinojosa, Christina O;
    • Hess, Kenneth R;
    • Cleeland, Charles S;
    • Bernstam, Elmer V;
    • Meric-Bernstam, Funda;
    • Hong, David S
    Publication type:
    journal article
    10
    11
    12

    Improved Outcomes Following Resection of Perihilar Cholangiocarcinoma: A 27-Year Experience.

    Published in:
    Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2025, v. 32, n. 6, p. 4352, doi. 10.1245/s10434-025-17075-5
    By:
    • Jain, Anish J.;
    • Lendoire, Mateo;
    • Haddad, Antony;
    • Tzeng, Ching-Wei D.;
    • Boyev, Artem;
    • Maki, Harufumi;
    • Chun, Yun Shin;
    • Arvide, Elsa M.;
    • Lee, Sunyoung;
    • Hu, Ian;
    • Pant, Shubham;
    • Javle, Milind;
    • Tran Cao, Hop S.;
    • Vauthey, Jean-Nicolas;
    • Newhook, Timothy E.
    Publication type:
    Article
    13

    Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer.

    Published in:
    2020
    By:
    • Voss, Martin H.;
    • Gordon, Michael S.;
    • Mita, Monica;
    • Rini, Brian;
    • Makker, Vicky;
    • Macarulla, Teresa;
    • Smith, David C.;
    • Cervantes, Andrés;
    • Puzanov, Igor;
    • Pili, Roberto;
    • Wang, Ding;
    • Jalal, Shadia;
    • Pant, Shubham;
    • Patel, Manish R.;
    • Neuwirth, Rachel l.;
    • Enke, Aaron;
    • Shou, Yaping;
    • Sedarati, Farhad;
    • Faller, Douglas V.;
    • Burris III, Howard A.
    Publication type:
    journal article
    14
    15
    16

    A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2023, v. 92, n. 2, p. 107, doi. 10.1007/s00280-023-04545-4
    By:
    • Piha-Paul, Sarina A.;
    • Tseng, Chieh;
    • Tran, Hai T.;
    • Gao, Meng;
    • Karp, Daniel D.;
    • Subbiah, Vivek;
    • Tsimberidou, Apostolia Maria;
    • Kawedia, Jitesh D.;
    • Fu, Siqing;
    • Pant, Shubham;
    • Yap, Timothy A.;
    • Morris, Van K.;
    • Kee, Bryan K.;
    • Blum Murphy, Mariela;
    • Lim, JoAnn;
    • Meric-Bernstam, Funda
    Publication type:
    Article
    17

    Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients.

    Published in:
    Cancer Medicine, 2021, v. 10, n. 15, p. 5041, doi. 10.1002/cam4.3870
    By:
    • Mohindroo, Chirayu;
    • Hasanov, Merve;
    • Rogers, Jane E.;
    • Dong, Wenli;
    • Prakash, Laura R.;
    • Baydogan, Seyda;
    • Mizrahi, Jonathan D.;
    • Overman, Michael J.;
    • Varadhachary, Gauri R.;
    • Wolff, Robert A.;
    • Javle, Milind M.;
    • Fogelman, David R.;
    • Lotze, Michael T.;
    • Kim, Michael P.;
    • Katz, Matthew H.G.;
    • Pant, Shubham;
    • Tzeng, Ching‐Wei D.;
    • McAllister, Florencia
    Publication type:
    Article
    18
    19
    20

    Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors.

    Published in:
    2016
    By:
    • Sarantopoulos, John;
    • Goel, Sanjay;
    • Chung, Vincent;
    • Munster, Pamela;
    • Pant, Shubham;
    • Patel, Manish;
    • Infante, Jeffrey;
    • Tawbi, Hussein;
    • Becerra, Carlos;
    • Bruce, Justine;
    • Kabbinavar, Fairooz;
    • Lockhart, A.;
    • Tan, Eugene;
    • Yang, Shu;
    • Carlson, Gary;
    • Scott, Jeffrey;
    • Sharma, Sunil;
    • Patel, Manish R;
    • Lockhart, A Craig;
    • Scott, Jeffrey W
    Publication type:
    journal article
    21
    22
    23

    A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors.

    Published in:
    Journal of Experimental & Clinical Cancer Research (17569966), 2022, v. 41, n. 1, p. 1, doi. 10.1186/s13046-022-02383-5
    By:
    • Chan, Stephen L.;
    • Schuler, Martin;
    • Kang, Yoon-Koo;
    • Yen, Chia-Jui;
    • Edeline, Julien;
    • Choo, Su Pin;
    • Lin, Chia-Chi;
    • Okusaka, Takuji;
    • Weiss, Karl-Heinz;
    • Macarulla, Teresa;
    • Cattan, Stéphane;
    • Blanc, Jean-Frederic;
    • Lee, Kyung-Hun;
    • Maur, Michela;
    • Pant, Shubham;
    • Kudo, Masatoshi;
    • Assenat, Eric;
    • Zhu, Andrew X.;
    • Yau, Thomas;
    • Lim, Ho Yeong
    Publication type:
    Article
    24
    25
    26
    27

    A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF‐10502‐01 for the treatment of advanced solid tumors.

    Published in:
    Cancer (0008543X), 2023, v. 129, n. 10, p. 1537, doi. 10.1002/cncr.34709
    By:
    • Janku, Filip;
    • Javle, Milind M.;
    • Sen, Shiraj;
    • Pant, Shubham;
    • Bramwell, Lindsay G.;
    • Subbiah, Vivek;
    • Way, Tracey;
    • Wages, David S.;
    • Wheeler, Catherine A.;
    • Suzuki, Takeaki;
    • Saeki, Kazunori;
    • Subach, Ruth Ann;
    • Madden, Timothy;
    • Maier, Gary;
    • Johansen, Mary J.;
    • Cheung, Kin;
    • Falchook, Gerald S.
    Publication type:
    Article
    28

    Incidence and reasons for late failure after allogeneic haematopoietic cell transplantation following BuCy2 in acute myeloid leukaemia.

    Published in:
    British Journal of Haematology, 2010, v. 148, n. 4, p. 623, doi. 10.1111/j.1365-2141.2009.07947.x
    By:
    • Pant, Shubham;
    • Hamadani, Mehdi;
    • Dodds, Anthony J.;
    • Szer, Jeffrey;
    • Crilley, Pamela A.;
    • Stevenson, Dustin;
    • Phillips, Gary;
    • Elder, Patrick;
    • Nivison-Smith, Ian;
    • Avalos, Belinda R.;
    • Penza, Sam;
    • Topolsky, David;
    • Sobecks, Ronald;
    • Kalaycio, Matt;
    • Bolwell, Brian J.;
    • Copelan, Edward A.
    Publication type:
    Article
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39

    First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors.

    Published in:
    Investigational New Drugs, 2022, v. 40, n. 5, p. 990, doi. 10.1007/s10637-022-01274-y
    By:
    • Bauer, Todd;
    • Cho, Byong Chul;
    • Heist, Rebecca;
    • Bazhenova, Lyudmila;
    • Werner, Theresa;
    • Goel, Sanjay;
    • Kim, Dong-Wan;
    • Adkins, Douglas;
    • Carvajal, Richard D.;
    • Alva, Ajjai;
    • Eaton, Keith;
    • Wang, Judy;
    • Liu, Yong;
    • Yan, Xiaohong;
    • Christensen, Jamie;
    • Neuteboom, Saskia;
    • Chao, Richard;
    • Pant, Shubham
    Publication type:
    Article
    40

    Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study.

    Published in:
    2022
    By:
    • Thein, Kyaw Zin;
    • Piha-Paul, Sarina A.;
    • Tsimberidou, Apostolia;
    • Karp, Daniel D.;
    • Janku, Filip;
    • Zarifa, Abdulrazzak;
    • Shah, Jatin;
    • Milton, Denái R.;
    • Bean, Stacie;
    • McQuinn, Lacey;
    • Gong, Jing;
    • Colen, Rivka;
    • Carter, Brett W.;
    • Subbiah, Vivek;
    • Ogbonna, Deby C.;
    • Pant, Shubham;
    • Meric-Bernstam, Funda;
    • Naing, Aung
    Publication type:
    Correction Notice
    41

    Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi‐arm phase Ib study.

    Published in:
    Investigational New Drugs, 2021, v. 39, n. 5, p. 1357, doi. 10.1007/s10637-021-01119-0
    By:
    • Thein, Kyaw Zin;
    • Piha-Paul, Sarina A.;
    • Tsimberidou, Apostolia;
    • Karp, Daniel D.;
    • Janku, Filip;
    • Zarifa, Abdulrazzak;
    • Shah, Jatin;
    • Milton, Denái R.;
    • Bean, Stacie;
    • McQuinn, Lacey;
    • Gong, Jing;
    • Colen, Rivka;
    • Carter, Brett W.;
    • Subbiah, Vivek;
    • Ogbonna, Deby C.;
    • Pant, Shubham;
    • Meric-Bernstam, Funda;
    • Naing, Aung
    Publication type:
    Article
    42

    A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors.

    Published in:
    Investigational New Drugs, 2021, v. 39, n. 4, p. 1089, doi. 10.1007/s10637-021-01094-6
    By:
    • Azaro, Analia;
    • Massard, Christophe;
    • Tap, William D.;
    • Cassier, Philippe A.;
    • Merchan, Jaime;
    • Italiano, Antoine;
    • Anderson, Bailey;
    • Yuen, Eunice;
    • Yu, Danni;
    • Oakley III, Gerard;
    • Benhadji, Karim A.;
    • Pant, Shubham
    Publication type:
    Article
    43

    Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC).

    Published in:
    Investigational New Drugs, 2021, v. 39, n. 1, p. 182, doi. 10.1007/s10637-020-01000-6
    By:
    • Hecht, J. Randolph;
    • Papadopoulos, Kyriakos P.;
    • Falchook, Gerald S.;
    • Patel, Manish R.;
    • Infante, Jeffrey R.;
    • Aljumaily, Raid;
    • Wong, Deborah J.;
    • Autio, Karen A.;
    • Wainberg, Zev A.;
    • Bauer, Todd M.;
    • Javle, Milind;
    • Pant, Shubham;
    • Bendell, Johanna;
    • Hung, Annie;
    • Ratti, Navneet;
    • VanVlasselaer, Peter;
    • Verma, Rakesh;
    • Leveque, Joseph;
    • Rao, Sujata;
    • Oft, Martin
    Publication type:
    Article
    44

    A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors.

    Published in:
    Investigational New Drugs, 2018, v. 36, n. 6, p. 1016, doi. 10.1007/s10637-018-0591-z
    By:
    • Aghajanian, Carol;
    • Bell-McGuinn, Katherine M.;
    • Burris, Howard A.;
    • Siu, Lillian L.;
    • Stayner, Lee-Ann;
    • Wheler, Jennifer J.;
    • Hong, David S.;
    • Kurkjian, Carla;
    • Pant, Shubham;
    • Santiago-Walker, Ademi;
    • Gauvin, Jennifer L.;
    • Antal, Joyce M.;
    • Opalinska, Joanna B.;
    • Morris, Shannon R.;
    • Infante, Jeffrey R.
    Publication type:
    Article
    45

    Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies.

    Published in:
    Investigational New Drugs, 2018, v. 36, n. 2, p. 248, doi. 10.1007/s10637-017-0499-z
    By:
    • Xiaofei Zhou;
    • Pant, Shubham;
    • Nemunaitis, John;
    • Lockhart, A. Craig;
    • Falchook, Gerald;
    • Bauer, Todd M.;
    • Patel, Manish;
    • Sarantopoulos, John;
    • Bargfrede, Michael;
    • Muehler, Andreas;
    • Rangachari, Lakshmi;
    • Bin Zhang;
    • Venkatakrishnan, Karthik
    Publication type:
    Article
    46
    47
    48
    49
    50